Isatuximab: Nursing Considerations for Use in the Treatment of Multiple Myeloma
Jenai Wilmoth, Kathleen Colson1, Franck Dubin
1Dana- Farber Cancer Institute.
Background:
Isatuximab is a CD38 monoclonal antibody approved for use in combination with pomalidomide plus dexamethasone to treat adults with relapsed/refractory multiple myeloma who have received at least two prior therapies. Because isatuximab is a relatively new treatment option, published guidelines for oncology nurses are limited.
Objectives:
This article provides nurses with guidance on all aspects of isatuximab administration and patient management to better support those receiving this treatment.
Methods:
Data from the ICARIA-MM (NCT02990338) clinical trial and additional nursing resources were collected and condensed into concise treatment and management recommendations for the care of patients with multiple myeloma undergoing treatment with isatuximab.
Findings:
Nursing care of patients prescribed isatuximab includes monitoring of clinical and laboratory parameters and requires knowledge and management of associated adverse events, including infusion reactions and neutropenia. This information could aid oncology nurses in providing optimal, treatment-specific education to patients and caregivers.
More Related Videos
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
07:24Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
Related Concept Videos
Myocarditis IV: Nursing Management
Myocarditis III: Medical Management
Nephrotic Syndrome III : Nursing Management
Tumor Immunotherapy
Kidney Transplant III: Nursing Management
Acute Kidney Injury VI: Nursing Management
